437 related articles for article (PubMed ID: 12860163)
1. Immunodeficiency and cancer: prospects for correction.
Hadden JW
Int Immunopharmacol; 2003 Aug; 3(8):1061-71. PubMed ID: 12860163
[TBL] [Abstract][Full Text] [Related]
2. Lymph node histology in head and neck cancer: impact of immunotherapy with IRX-2.
Meneses A; Verastegui E; Barrera JL; de la Garza J; Hadden JW
Int Immunopharmacol; 2003 Aug; 3(8):1083-91. PubMed ID: 12860165
[TBL] [Abstract][Full Text] [Related]
3. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.
Khawli LA; Hu P; Epstein AL
Handb Exp Pharmacol; 2008; (181):291-328. PubMed ID: 18071951
[TBL] [Abstract][Full Text] [Related]
4. A trial of IRX-2 in patients with squamous cell carcinomas of the head and neck.
Hadden J; Verastegui E; Barrera JL; Kurman M; Meneses A; Zinser JW; de la Garza J; Hadden E
Int Immunopharmacol; 2003 Aug; 3(8):1073-81. PubMed ID: 12860164
[TBL] [Abstract][Full Text] [Related]
5. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside.
O'Malley BW; Li D; McQuone SJ; Ralston R
Laryngoscope; 2005 Mar; 115(3):391-404. PubMed ID: 15744147
[TBL] [Abstract][Full Text] [Related]
6. [Antitumoral action of interferons and interleukins in combination with radiotherapy. Part I: immunologic basis].
Herskind C; Fleckenstein K; Lohr J; Li CY; Wenz F; Lohr F
Strahlenther Onkol; 2004 Apr; 180(4):187-93. PubMed ID: 15057428
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-21 triggers both cellular and humoral immune responses leading to therapeutic antitumor effects against head and neck squamous cell carcinoma.
Nakano H; Kishida T; Asada H; Shin-Ya M; Shinomiya T; Imanishi J; Shimada T; Nakai S; Takeuchi M; Hisa Y; Mazda O
J Gene Med; 2006 Jan; 8(1):90-9. PubMed ID: 16097036
[TBL] [Abstract][Full Text] [Related]
8. T cell targeted immune enhancement yields effective T cell adjuvants.
Naylor PH; Hadden JW
Int Immunopharmacol; 2003 Aug; 3(8):1205-15. PubMed ID: 12860176
[TBL] [Abstract][Full Text] [Related]
9. Molecular immunological approaches to biotherapy of human cancers--a review, hypothesis and implications.
Becker Y
Anticancer Res; 2006; 26(2A):1113-34. PubMed ID: 16619514
[TBL] [Abstract][Full Text] [Related]
10. Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy.
Peggs KS; Quezada SA; Allison JP
Immunol Rev; 2008 Aug; 224():141-65. PubMed ID: 18759925
[TBL] [Abstract][Full Text] [Related]
11. IRX-2 and thymosin alpha1 (Zadaxin) increase T lymphocytes in T lymphocytopenic mice and humans.
Hadden JW; Verastegui E; Hadden E
Ann N Y Acad Sci; 2007 Sep; 1112():245-55. PubMed ID: 17600288
[TBL] [Abstract][Full Text] [Related]
12. Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration.
Bracci L; Moschella F; Sestili P; La Sorsa V; Valentini M; Canini I; Baccarini S; Maccari S; Ramoni C; Belardelli F; Proietti E
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):644-53. PubMed ID: 17255288
[TBL] [Abstract][Full Text] [Related]
13. Histologic findings in patients with head and neck squamous cell carcinoma receiving perilymphatic natural cytokine mixture (IRX-2) prior to surgery.
Meneses A; Verastegui E; Barrera JL; Zinser J; de la Garza J; Hadden JW
Arch Pathol Lab Med; 1998 May; 122(5):447-54. PubMed ID: 9593347
[TBL] [Abstract][Full Text] [Related]
14. [The repetitive immune cell transfer therapy combining non-myelosuppressive chemotherapy for patients with advanced and refractory cancer].
Toh U; Fujii T; Tayama K; Yanaga H; Yokoyama G; Yamaguchi M; Horiuchi H; Sasatomi T; Takamori S; Shirouzu K; Seki N; Yamana H
Gan To Kagaku Ryoho; 2004 Oct; 31(11):1649-51. PubMed ID: 15553672
[TBL] [Abstract][Full Text] [Related]
15. Augmenting major histocompatibility complex class I expression by murine tumors in vivo enhances antitumor immunity induced by an active immunotherapy strategy.
Merritt RE; Yamada RE; Crystal RG; Korst RJ
J Thorac Cardiovasc Surg; 2004 Feb; 127(2):355-64. PubMed ID: 14762342
[TBL] [Abstract][Full Text] [Related]
16. Ampligen: a potential toll-like 3 receptor adjuvant for immunotherapy of cancer.
Jasani B; Navabi H; Adams M
Vaccine; 2009 May; 27(25-26):3401-4. PubMed ID: 19200817
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of T cell and natural killer cell function by adenosine and its contribution to immune evasion by tumor cells (Review).
Hoskin DW; Mader JS; Furlong SJ; Conrad DM; Blay J
Int J Oncol; 2008 Mar; 32(3):527-35. PubMed ID: 18292929
[TBL] [Abstract][Full Text] [Related]
18. Enhancement of immunologic tumor regression by intratumoral administration of dendritic cells in combination with cryoablative tumor pretreatment and Bacillus Calmette-Guerin cell wall skeleton stimulation.
Udagawa M; Kudo-Saito C; Hasegawa G; Yano K; Yamamoto A; Yaguchi M; Toda M; Azuma I; Iwai T; Kawakami Y
Clin Cancer Res; 2006 Dec; 12(24):7465-75. PubMed ID: 17189420
[TBL] [Abstract][Full Text] [Related]
19. Cancer-associated immune-mediated syndromes: Pathogenic values and clinical implementation.
Suchkov SV; Petrunin DD; Kostalevskaya AV; Kachkov IA; Elbeik T; Matsuura E; Paltsev MA
Biomed Pharmacother; 2007 Jul; 61(6):323-37. PubMed ID: 17656060
[TBL] [Abstract][Full Text] [Related]
20. CpG therapy is superior to BCG in an orthotopic bladder cancer model and generates CD4+ T-cell immunity.
Mangsbo SM; Ninalga C; Essand M; Loskog A; Tötterman TH
J Immunother; 2008 Jan; 31(1):34-42. PubMed ID: 18157010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
